Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded at StockNews.com
Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded at StockNews.com
Supernus Pharmaceuticals (NASDAQ:SUPN – Get Rating) was upgraded by stock analysts at StockNews.com from a "buy" rating to a "strong-buy" rating in a report issued on Friday.
在周五发布的一份报告中，斯托克新闻网的股票分析师将Supernus PharmPharmticals(纳斯达克代码：SUPN-GET Rating)的评级从“买入”上调至“强力买入”。
Separately, Piper Sandler lifted their price objective on Supernus Pharmaceuticals from $33.00 to $38.00 and gave the stock an "overweight" rating in a research report on Wednesday.
另外，派珀·桑德勒在周三的一份研究报告中将Supernus PharmPharmticals的目标价从33.00美元上调至38.00美元，并给予该股“增持”评级。
Supernus Pharmaceuticals Price Performance
Supernus制药价格表现
Shares of NASDAQ SUPN traded down $0.65 on Friday, hitting $34.39. The company's stock had a trading volume of 206,464 shares, compared to its average volume of 417,010. The stock has a 50 day moving average of $31.48 and a 200-day moving average of $30.26. The company has a market capitalization of $1.84 billion, a price-to-earnings ratio of 34.05 and a beta of 1.04. Supernus Pharmaceuticals has a 12-month low of $24.95 and a 12-month high of $36.08.
上周五，纳斯达克股价下跌0.65美元，至34.39美元。该公司股票的成交量为206,464股，而其平均成交量为417,010股。该股的50日移动均线切入位在31.48美元，200日移动均线切入位在30.26美元。该公司市值18.4亿美元，市盈率为34.05倍，贝塔系数为1.04。Supernus PharmPharmticals的12个月低点为24.95美元，12个月高位为36.08美元。
Insiders Place Their Bets
内部人士下注
In other Supernus Pharmaceuticals news, VP Tami Tillotson Martin sold 5,000 shares of the stock in a transaction on Monday, August 22nd. The stock was sold at an average price of $35.98, for a total transaction of $179,900.00. Following the transaction, the vice president now owns 87,220 shares of the company's stock, valued at approximately $3,138,175.60. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Supernus Pharmaceuticals news, VP Tami Tillotson Martin sold 5,000 shares of Supernus Pharmaceuticals stock in a transaction dated Monday, August 22nd. The stock was sold at an average price of $35.98, for a total value of $179,900.00. Following the completion of the sale, the vice president now owns 87,220 shares in the company, valued at approximately $3,138,175.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Jack A. Khattar sold 39,431 shares of the stock in a transaction dated Tuesday, August 9th. The stock was sold at an average price of $31.15, for a total transaction of $1,228,275.65. Following the transaction, the chief executive officer now owns 724,978 shares in the company, valued at $22,583,064.70. The disclosure for this sale can be found here. In the last three months, insiders sold 66,733 shares of company stock valued at $2,161,863. Company insiders own 7.99% of the company's stock.
在Supernus PharmPharmticals的其他消息中，副总裁Tami Tillotson Martin在8月22日星期一的一笔交易中出售了5000股该公司股票。该股以35.98美元的平均价格出售，总成交金额为179,900.00美元。交易完成后，副总经理总裁现在持有该公司87,220股股票，价值约3,138,175.60美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可以在美国证券交易委员会的网站上看到。在Supernus制药公司的其他消息中，副总裁Tami Tillotson Martin在一笔日期为8月22日星期一的交易中出售了5000股Supernus制药公司的股票。这只股票的平均售价为35.98美元，总价值为179,900.00美元。出售完成后，副总经理总裁现在拥有该公司87,220股股份，价值约3,138,175.60美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，可以通过以下链接访问该文件。此外，首席执行官杰克·哈塔尔在日期为8月9日(星期二)的交易中出售了39,431股该股。该股以31.15美元的平均价格出售，总成交金额为1228275.65美元。交易完成后，这位首席执行官现在拥有该公司724,978股，价值22,583,064.70美元。此次拍卖的披露信息可在此处找到。在过去的三个月里，内部人士出售了66,733股公司股票，价值2,161,863美元。公司内部人士持有该公司7.99%的股份。
Institutional Trading of Supernus Pharmaceuticals
Supernus制药公司的机构交易
Institutional investors and hedge funds have recently made changes to their positions in the company. Polaris Capital Management LLC increased its position in Supernus Pharmaceuticals by 8,769.9% during the 2nd quarter. Polaris Capital Management LLC now owns 2,918,196 shares of the specialty pharmaceutical company's stock worth $45,611,000 after purchasing an additional 2,885,296 shares in the last quarter. Woodline Partners LP acquired a new stake in shares of Supernus Pharmaceuticals in the first quarter worth $15,689,000. Stephens Investment Management Group LLC raised its stake in shares of Supernus Pharmaceuticals by 27.2% in the 4th quarter. Stephens Investment Management Group LLC now owns 1,577,980 shares of the specialty pharmaceutical company's stock valued at $46,014,000 after acquiring an additional 337,902 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of Supernus Pharmaceuticals by 108.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 550,081 shares of the specialty pharmaceutical company's stock valued at $17,779,000 after acquiring an additional 285,737 shares in the last quarter. Finally, Millennium Management LLC purchased a new stake in Supernus Pharmaceuticals during the 2nd quarter worth $7,063,000. 99.81% of the stock is currently owned by institutional investors and hedge funds.
机构投资者和对冲基金最近对他们在该公司的头寸进行了调整。北极星资本管理公司在第二季度将其在Supernus制药公司的头寸增加了8769.9%。北极星资本管理有限责任公司在上个季度额外购买了2885,296股后，现在拥有2918,196股这家专业制药公司的股票，价值45,611,000美元。Woodline Partners LP在第一季度收购了Supernus PharmPharmticals价值15，68.9万美元的新股份。斯蒂芬斯投资管理集团LLC在第四季度将其在Supernus PharmPharmticals的股份增加了27.2%。斯蒂芬斯投资管理集团现在拥有1,577,980股这家专业制药公司的股票，价值46,014,000美元，在此期间又购买了337,902股。高盛股份有限公司在第一季度增持了108.1%的Supernus PharmPharmticals股票。高盛股份有限公司在上个季度增持了285,737股后，现在拥有550,081股这家专业制药公司的股票，价值17,779,000美元。最后，千禧管理有限责任公司在第二季度购买了Supernus制药公司价值706.3万美元的新股份。该公司99.81%的股票目前由机构投资者和对冲基金持有。
About Supernus Pharmaceuticals
关于Supernus制药公司
(Get Rating)
(获取评级)
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.
Supernus制药公司是一家生物制药公司，在美国专注于治疗中枢神经系统(CNS)疾病的产品的开发和商业化。它的商业产品是Trokendi XR，这是一种用于治疗癫痫和预防偏头痛的托吡酯缓释剂；奥克泰拉XR是一种缓释型奥卡西平，用于单一疗法治疗6至17岁的成人和儿童部分发作癫痫。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Supernus Pharmaceuticals (SUPN)
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
- Is Alcoa A Buy After Strong Q2 Results And More Share Buybacks?
- Will Royal Caribbean's Broadband Partnership Drive Revenue?
- 免费获取StockNews.com关于Supernus制药公司的研究报告(SUPN)
- 霍梅尔在这些水平上看起来很便宜
- 露露柠檬将飙升至9月
- 耐克股票会被超卖，但仍被高估吗？
- 美国铝业是在第二季度业绩强劲和更多股票回购之后买入的吗？
- 皇家加勒比的宽带合作能否推动收入增长？
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
获得Supernus PharmPharmticals Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Supernus制药公司和相关公司的最新新闻和分析师评级的每日摘要。